A peer‑reviewed analysis led by GigHz founder reveals that three‑quarters of FDA authorizations for AI‑enabled medical devices between 2018 and 2026 were granted for radiology applications. The study examined 1,430 authorization records, highlighting radiology’s early adoption of AI for image interpretation, workflow automation, and diagnostic assistance. Researchers note that the concentration reflects both the data‑rich nature of imaging and regulatory familiarity with algorithmic decision‑support tools.

The findings raise questions about the broader diffusion of AI across other clinical domains such as pathology, cardiology, and primary care. GigHz’s report suggests that expanding high‑quality labeled datasets and establishing clear safety frameworks will be crucial for AI to achieve comparable regulatory traction in these underserved specialties.

This story was written by a language model from reporting by BioSpace. Check the original before quoting it.